Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
Overview
This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Care Provider, Investigator)
- Study Primary Completion Date: April 20, 2022
Detailed Description
This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features. After diagnosis of preeclampsia with severe features and decision made to proceed with induction of labor. Patients were approached about study and if consented then were then randomized to placebo or nifedipine 30XL daily until delivery occurred.
Interventions
- Drug: Nifedipine 30 MG
- Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
- Drug: Placebos
- At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
Arms, Groups and Cohorts
- Active Comparator: Nifedipine 30MG
- Oral administration of 30mg Nifedipine XL q24 hours until delivery
- Placebo Comparator: Placebo
- Matching placebo group q24hrs until delivery
Clinical Trial Outcome Measures
Primary Measures
- Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo
- Time Frame: Between enrollment and delivery, assessed up to 18 weeks
- Measured acute antihypertension therapy between enrollment and delivery
Secondary Measures
- Number of Participants Stratified by Route of Delivery
- Time Frame: At delivery
- Number of Participants With Various Indications for Cesarean Delivery
- Time Frame: Between enrollment and delivery, assessed up to 18 weeks
- Some participants could have more than one indication for Cesarean Delivery.
- Number of Participants With Hypotension of ≥30% Decrease in Blood Pressure From Baseline Following Acute Antihypertensive Therapy
- Time Frame: Between enrollment and delivery, assessed up to 18 weeks
- Number of Participants Who Required Acute Antihypertension Treatments Postpartum
- Time Frame: At delivery
Participating in This Clinical Trial
Inclusion Criteria
- Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria. – Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures. Exclusion Criteria:
- Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder. – Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor – Participation in another trial that affects the primary outcome without prior approval – Physician/provider or patient refusal – Participation in this trial in a prior pregnancy – Triplet or higher order pregnancy
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Ohio State University
- Provider of Information About this Clinical Study
- Principal Investigator: Kara M Rood, MD, MD, Assistant Professor – Ohio State University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.